Practical guidance for use of oral semaglutide in primary care: a narrative review-Reference-Cited by-同舟云学术

Practical guidance for use of oral semaglutide in primary care: a narrative review

Published:2020-07-09 Issue:8 Volume:132 Page:687-696
ISSN:0032-5481
Container-title:Postgraduate Medicine
language:en
Short-container-title:Postgraduate Medicine

Author:

Morales Javier¹^ORCID,Shubrook Jay H.²^ORCID,Skolnik Neil³

Affiliation:

1. Department of Medicine, Donald and Barbara Zucker School of Medicine, Hofstra/Northwell University, New York, NY, USA

2. Primary Care Department, College of Osteopathic Medicine, Touro University California, Vallejo, CA, USA

3. Abington Family Medicine, Jenkintown, PA, USA

Funder

Novo Nordisk Inc

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00325481.2020.1788340

Reference75 articles.

1. Centers for Disease Control and Prevention (CDC). National diabetes statistics report. 2017; [cited 2020 Apr 29]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf

2. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014

3. Economic Costs of Diabetes in the U.S. in 2017

4. The Increasing Role of Primary Care Physicians in Caring for Patients With Type 2 Diabetes Mellitus

5. Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2024-07-05

2. Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection;Canadian Journal of Cardiology;2023-12

3. Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions;Diabetes Spectrum;2022-11-01

4. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes;Reviews in Endocrine and Metabolic Disorders;2022-07-15

5. Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6;Postgraduate Medicine;2022-06-21